MabGenesis, Inc.
Status: Publicly traded
Last reviewed: November 2026
Direct answer
MabGenesis, Inc. is publicly traded on JPX under the ticker 653A.T.
MabGenesis Inc., a biopharmaceutical company, engages in the research, discovery, development, and commercialization of therapeutic monoclonal antibody drugs for human and animal healthcare applications in Japan. The company offers proprietary antibody discovery platforms, including MOURA Libraries and IMPACT antibody isolation technology, to develop antibody therapeutics. The company was incorporated in 2019 and is...
Can you invest in MabGenesis, Inc.?
Yes. MabGenesis, Inc. is publicly traded on JPX under the ticker 653A.T.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for MabGenesis, Inc.
Detailed equity research is provided by MarketSnap.